drugset / Trial / NCT00093041
Zalutumumab in Head and Neck Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.
Timeline
- Start
- 2003-12-01
- Primary completion
- 2005-01-12
- Completion
- 2005-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zalutumumab | Monoclonal antibody | 0.15 mg/kg | — |
| Subject | Zalutumumab | Monoclonal antibody | 0.5 mg/kg | — |
| Subject | Zalutumumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Zalutumumab | Monoclonal antibody | 2 mg/kg | — |
| Subject | Zalutumumab | Monoclonal antibody | 4 mg/kg | — |
| Subject | Zalutumumab | Monoclonal antibody | 8 mg/kg | — |